These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 31175431)

  • 1. Current issues regarding the application of recombinant lactic acid bacteria to mucosal vaccine carriers.
    Takahashi K; Orito N; Tokunoh N; Inoue N
    Appl Microbiol Biotechnol; 2019 Aug; 103(15):5947-5955. PubMed ID: 31175431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytoplasmic expression of a model antigen with M Cell-Targeting moiety in lactic acid bacteria and implication of the mechanism as a mucosal vaccine via oral route.
    Oh SH; Kim SH; Jeon JH; Kim EB; Lee NK; Beck S; Choi YJ; Kang SK
    Vaccine; 2021 Jul; 39(30):4072-4081. PubMed ID: 34127296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mucosal vaccination and therapy with genetically modified lactic acid bacteria.
    Wells J
    Annu Rev Food Sci Technol; 2011; 2():423-45. PubMed ID: 22129390
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    LeCureux JS; Dean GA
    mSphere; 2018; 3(3):. PubMed ID: 29769376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lactic acid bacteria--20 years exploring their potential as live vectors for mucosal vaccination.
    Wyszyńska A; Kobierecka P; Bardowski J; Jagusztyn-Krynicka EK
    Appl Microbiol Biotechnol; 2015 Apr; 99(7):2967-77. PubMed ID: 25750046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polymeric penetration enhancers promote humoral immune responses to mucosal vaccines.
    Klein K; Mann JF; Rogers P; Shattock RJ
    J Control Release; 2014 Jun; 183():43-50. PubMed ID: 24657807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene-based neonatal immune priming potentiates a mucosal adenoviral vaccine encoding mycobacterial Ag85B.
    Dai G; Rady HF; Huang W; Shellito JE; Mason C; Ramsay AJ
    Vaccine; 2016 Dec; 34(50):6267-6275. PubMed ID: 27823900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of live bacterial vaccine vectors for antigen delivery: potential and limitations.
    Medina E; Guzmán CA
    Vaccine; 2001 Feb; 19(13-14):1573-80. PubMed ID: 11166877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant Strategies for Lactic Acid Bacterial Mucosal Vaccines.
    Vilander AC; Dean GA
    Vaccines (Basel); 2019 Oct; 7(4):. PubMed ID: 31623188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant lactic acid bacteria as promising vectors for mucosal vaccination.
    Qiao N; Du G; Zhong X; Sun X
    Exploration (Beijing); 2021 Oct; 1(2):20210026. PubMed ID: 37323212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lactic acid bacteria - promising vaccine vectors: possibilities, limitations, doubts.
    Szatraj K; Szczepankowska AK; Chmielewska-Jeznach M
    J Appl Microbiol; 2017 Aug; 123(2):325-339. PubMed ID: 28295939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Live bacterial delivery systems for development of mucosal vaccines.
    Thole JE; van Dalen PJ; Havenith CE; Pouwels PH; Seegers JF; Tielen FD; van der Zee MD; Zegers ND; Shaw M
    Curr Opin Mol Ther; 2000 Feb; 2(1):94-9. PubMed ID: 11249657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protection against human papillomavirus type 16-induced tumors in mice using non-genetically modified lactic acid bacteria displaying E7 antigen at its surface.
    Ribelles P; Benbouziane B; Langella P; Suárez JE; Bermúdez-Humarán LG
    Appl Microbiol Biotechnol; 2013 Feb; 97(3):1231-9. PubMed ID: 23212671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Norovirus (NoV) specific protective immune responses induced by recombinant P dimer vaccine are enhanced by the mucosal adjuvant FlaB.
    Verma V; Tan W; Puth S; Cho KO; Lee SE; Rhee JH
    J Transl Med; 2016 May; 14(1):135. PubMed ID: 27184355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant vaccine delivery systems and encoded vaccines.
    Stover CK
    Curr Opin Immunol; 1994 Aug; 6(4):568-71. PubMed ID: 7946044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The mucosal immune system for vaccine development.
    Lamichhane A; Azegamia T; Kiyonoa H
    Vaccine; 2014 Nov; 32(49):6711-23. PubMed ID: 25454857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Engineering Tools for the Development of Recombinant Lactic Acid Bacteria.
    Cho SW; Yim J; Seo SW
    Biotechnol J; 2020 Jun; 15(6):e1900344. PubMed ID: 31995278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gold nanoparticles and vaccine development.
    Salazar-González JA; González-Ortega O; Rosales-Mendoza S
    Expert Rev Vaccines; 2015; 14(9):1197-211. PubMed ID: 26152550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant lactic acid bacteria as mucosal biotherapeutic agents.
    Daniel C; Roussel Y; Kleerebezem M; Pot B
    Trends Biotechnol; 2011 Oct; 29(10):499-508. PubMed ID: 21665301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant vaccines.
    Barnard RT
    Expert Rev Vaccines; 2010 May; 9(5):461-3. PubMed ID: 20450319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.